bluebird bio, Inc. (NASDAQ:BLUE) insider Nick Leschly sold 7,050 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $145.14, for a total value of $1,023,237.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Nick Leschly also recently made the following trade(s):

  • On Tuesday, October 17th, Nick Leschly sold 10,823 shares of bluebird bio stock. The stock was sold at an average price of $145.05, for a total value of $1,569,876.15.
  • On Friday, September 1st, Nick Leschly sold 46,833 shares of bluebird bio stock. The stock was sold at an average price of $122.27, for a total value of $5,726,270.91.
  • On Wednesday, August 30th, Nick Leschly sold 25,667 shares of bluebird bio stock. The stock was sold at an average price of $115.18, for a total value of $2,956,325.06.

bluebird bio, Inc. (NASDAQ BLUE) traded up 0.64% during trading on Tuesday, hitting $141.25. 671,819 shares of the stock traded hands. The company’s market capitalization is $6.44 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $145.70. The company’s 50 day moving average is $131.35 and its 200 day moving average is $104.71.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the previous year, the business earned ($1.59) earnings per share. The company’s revenue was up 977.4% on a year-over-year basis. On average, equities analysts forecast that bluebird bio, Inc. will post ($6.80) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/nick-leschly-sells-7050-shares-of-bluebird-bio-inc-blue-stock.html.

Several equities analysts have recently issued reports on the company. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective for the company in a research report on Monday, October 16th. Jefferies Group LLC reiterated a “hold” rating and set a $126.00 price objective on shares of bluebird bio in a research report on Wednesday, October 11th. Maxim Group reiterated a “buy” rating and set a $170.00 price objective (up from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Leerink Swann reissued an “outperform” rating and set a $145.00 target price (up previously from $120.00) on shares of bluebird bio in a report on Friday, October 6th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $186.00 target price on shares of bluebird bio in a report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. bluebird bio currently has a consensus rating of “Hold” and a consensus target price of $118.81.

Institutional investors have recently added to or reduced their stakes in the stock. QS Investors LLC grew its position in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares in the last quarter. Bank of Montreal Can grew its position in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares in the last quarter. Turner Investments LLC bought a new position in bluebird bio in the second quarter valued at $184,000. SG Americas Securities LLC grew its position in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. bought a new position in bluebird bio in the second quarter valued at $210,000.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.